Contrave and Mounjaro are both FDA-approved for weight management, but they work through completely different mechanisms and produce very different results. If you’re trying to understand which one makes more sense for your situation, the comparison is worth taking seriously because the gap between them in terms of clinical outcomes is substantial.<\/p>\n
Contrave is a fixed-dose combination of bupropion and naltrexone. Bupropion is an antidepressant that affects dopamine and norepinephrine signaling. Naltrexone is an opioid antagonist used in addiction medicine. Together, they’re thought to reduce food cravings and appetite by acting on reward and hunger pathways in the brain. Contrave has been FDA-approved for chronic weight management since 2014 and is taken as an oral tablet, typically working up to four tablets per day over a gradual titration schedule.<\/p>\n
Mounjaro is the brand name for tirzepatide, a dual GIP and GLP-1 receptor agonist manufactured by Eli Lilly. It was originally approved for type 2 diabetes management and later approved under the name Zepbound specifically for chronic weight management in adults with obesity or overweight with a weight-related condition. It’s administered as a once-weekly subcutaneous injection and works by mimicking two gut hormones that regulate appetite, gastric emptying, and insulin secretion simultaneously.<\/p>\n
The mechanism difference matters. Contrave works centrally, targeting brain chemistry involved in cravings and reward. Tirzepatide works both centrally and peripherally, affecting appetite signaling in the brain while also slowing how quickly food moves through the stomach and improving metabolic function throughout the body.<\/p>\n
This is where the comparison becomes most striking. Contrave clinical trials showed average weight loss of around 4 to 5 percent of body weight over one year in patients who also followed a reduced-calorie diet and exercise program. That’s a modest but real result for patients with more limited weight loss goals.<\/p>\n
Tirzepatide’s results in the SURMOUNT trials are in a different category entirely. Published data in the New England Journal of Medicine showed that patients on the highest dose of tirzepatide lost an average of 22.5 percent of their body weight over 72 weeks. Even at lower doses, tirzepatide consistently outperformed older weight loss medications by a wide margin. For a patient weighing 250 pounds, a 5 percent loss means 12 pounds. A 20 percent loss means 50 pounds. That difference is clinically and practically significant.<\/p>\n
Contrave’s most common side effects include nausea, constipation, headache, insomnia, dry mouth, and dizziness. It carries a black box warning for increased suicidal thoughts in young adults, consistent with bupropion’s antidepressant classification. It’s contraindicated in patients with a history of seizure disorders, eating disorders involving purging, or those currently taking monoamine oxidase inhibitors. Blood pressure can increase on Contrave, so monitoring is important.<\/p>\n
Tirzepatide’s most common side effects are gastrointestinal, particularly nausea, vomiting, diarrhea, and constipation, most pronounced during dose escalation and typically improving over time. Serious but less common risks include pancreatitis and a theoretical thyroid C-cell tumor risk based on animal studies, which means it’s contraindicated in patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2.<\/p>\n
For patients managing other conditions alongside weight loss, it’s worth knowing how tirzepatide interacts with existing medications. The article on Zepbound and metformin<\/a> covers one common combination, and the article on tirzepatide and thyroid medication<\/a> addresses another frequent question.<\/p>\n One reason some patients consider Contrave over injectable options is the convenience of a pill. No needles, no refrigeration, no injection site rotation. For patients with needle anxiety or practical concerns about injectable medications, that’s a real factor.<\/p>\nThe Oral vs Injectable Question<\/h3>\n